UConn gene discovery moves closer to treating neuromuscular disease, holds promise for weight loss
The challenge of the obesity epidemic is widespread and one that even pediatricians face constantly,” a Connecticut doctor ...
pharmaphorum5y
Roche joins others in dropping myostatin inhibitor for DMD
The prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned development of RG6206, a myostatin inhibitor. The Swiss group revealed the ...
pharmaphorum21d
Pfizer takes muscular dystrophy drug into phase II
A few years later, a clinical trial of a myostatin inhibitor called stamulumab (MYO-029) developed by Wyeth (which was acquired by Pfizer in 2009) showed some promise in early trials but was ...
Nature1mon
First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon
Approval would upend two decades of failure for myostatin pathway inhibitors, a class of drugs that grows skeletal muscle. Beyond the first regulatory decision for apitegromab, companies are ...
Scholar Rock (SRRK) Projected to Post Earnings on Tuesday
Scholar Rock (NASDAQ:SRRK – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on ...
Yahoo6d
UConn gene discovery moves closer to treating neuromuscular disease, holds promise for weight loss
Based on the trial results, Scholar Rock, is now seeking FDA approval for their myostatin inhibitor, which is based on a fundamental mechanism discovered by Lee. “I could not be more excited to ...